Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Diasol Inc
WARNING LETTER
•Diasol Inc•June 15, 2017

Diasol Inc – FDA Warning Letter, Jun 15, 2017

Record Details

An FDA inspection of Diasol Inc.'s Phillipsburg, NJ facility from May 8 to June 15, 2017, revealed that the firm's manufactured and repacked dialysis concentrates (Dryasol, CitriSol, Diasol Acid Concentrates, Sodium Bicarbonate) are adulterated devices under 21 U.S.C. § 351(h) due to non-conformity with Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) regulation (21 CFR Part 820). Key violations include failure to establish and maintain procedures for finished device acceptance and documentation (21 CFR 820.80(d)&(e)), leading to product shipment before final inspection. The firm also failed to establish and implement procedures for controlling nonconforming product (21 CFR 820.90), resulting in out-of-specification products being released without proper documentation or rework. Additionally, Diasol Inc. failed to validate critical processes like mixing times and cleaning activities (21 CFR 820.75(a)), ensure suitable building design (21 CFR 820.70(f)) with issues like pest ingress and insulation problems, adequately control nonconforming materials by segregating them (21 CFR 820.90), and maintain document control procedures (21 CFR 820.40(a)) as essential documents were not available at required locations. The firm's responses to several observations were deemed inadequate. Prompt corrective actions are required within fifteen working days, with a detailed plan and timeline. Failure to comply may result in regulatory actions such as seizure, injunction, civil money penalties, and impact on federal contracts, premarket approvals, and Certificates to Foreign Governments.

Company
Diasol Inc
Inspection date
June 15, 2017
Product type
Devices
Office
New England District Office
Person
  • Joseph S. Matrisciano (Program Division Director)
View Company Profile

ID · 7f3038bf-0607-4387-833b-f2c8bfe110b1

Violation Codes9
21 U.S.C. 321(h)21 U.S.C. 351(h)21 CFR 82021 CFR 820.80(d)21 CFR 820.80(e)21 CFR 820.9021 CFR 820.75(a)21 CFR 820.70(f)21 CFR 820.40(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Diasol Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.